Form 4: Stoke Therapeutics CMO Sells Shares for Tax Obligations

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 2,805 shares of common stock to cover tax withholding liabilities related to restricted stock unit vesting.

Summary

• Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc. (STOK), reported a sale of 2,805 shares of common stock.
• The transaction occurred on August 18, 2025, at a weighted average price of $18.238 per share.
• The shares were sold in multiple transactions with prices ranging from $18.00 to $18.50 per share.
• The sale was an issuer-mandated transaction to satisfy tax withholding liabilities associated with the vesting and settlement of restricted stock units.
• Following this transaction, Barry Ticho directly beneficially owns 23,970 shares of Stoke Therapeutics common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-scheduled.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it's for a non-discretionary tax purpose and executed under a 10b5-1 plan, which typically does not signal negative sentiment from the insider. The reduction in ownership is minimal.

Positives

• The sale was an issuer-mandated transaction for tax purposes, not a discretionary sale by the insider, which suggests no negative sentiment towards the company's future.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged, non-discretionary sale.

Negatives

• The transaction results in a slight reduction of insider ownership, although it is for a specific tax-related purpose.

Risks

• No specific risks are detailed in this Form 4 filing beyond the inherent market risks associated with stock ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This transaction is a routine insider filing for tax purposes and does not reflect broader industry trends or competitive positioning within the biotechnology sector. It is a standard event for executives receiving equity compensation.

Comparison to Industry Standards

• Insider sales for tax withholding are common across all industries, including biotechnology, when restricted stock units or other equity awards vest.
• The volume of shares sold (2,805) is relatively small compared to the total shares outstanding for a publicly traded company like Stoke Therapeutics, indicating minimal market impact.
• Similar tax-related sales are frequently observed in filings for executives at comparable biotech firms such as Sarepta Therapeutics (SRPT) or Alnylam Pharmaceuticals (ALNY) when equity compensation vests.

Stakeholder Impact

• Shareholders: The sale is a routine tax-related transaction and is unlikely to have a significant impact on existing shareholders.
• Employees: No direct impact on employees is indicated by this filing.
• Management: The Chief Medical Officer's direct ownership remains substantial after the transaction, aligning his interests with shareholders.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and generally do not indicate a change in the company's fundamentals or the insider's long-term view. Therefore, it provides no new information that would warrant a change in investment recommendation based solely on this filing. Investors should continue to evaluate the company based on its financial performance, pipeline, and market conditions.

Keywords

Stoke Therapeutics, STOK, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Barry Ticho, Chief Medical Officer, Biotechnology